Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Online First

September 11, 2021

Correspondence response
Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Aringer et al
Free

Martin Aringer, Karen Costenbader, Nicolai Leuchten, Thomas Dörner, Sindhu R Johnson

doi: 10.1136/annrheumdis-2021-221374

August 23, 2021

Correspondence
Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al
Free

Elisa Gremese, Gianfranco Ferraccioli

doi: 10.1136/annrheumdis-2021-220932
Correspondence response
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al
Free

Zachary S Wallace, Jeffrey A Sparks, Philip C Robinson, Pedro M Machado, Jinoos Yazdany

doi: 10.1136/annrheumdis-2021-220960

August 13, 2021

Correspondence
Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” by Sparks et al

Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed

doi: 10.1136/annrheumdis-2021-221146
Correspondence response
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al
Free

Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Philip C Robinson, Pedro M Machado, Jinoos Yazdany

doi: 10.1136/annrheumdis-2021-221157

August 03, 2021

Correspondence response
Response to: Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Whittall Garcia et al
Free

Laura Whittall-Garcia, Dafna D Gladman, Murray Urowitz, Jiandong Su, Zahi Touma, Sindhu R Johnson

doi: 10.1136/annrheumdis-2021-221014
Correspondence
Correspondence on “New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE” by Whittall Garcia et al
Free

Guillermo J Pons-Estel, Manuel F. Ugarte-Gil, Guillermina B Harvey, Bernardo A Pons-Estel, Graciela S Alarcón

doi: 10.1136/annrheumdis-2021-220994
Correspondence response
Response to: Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Fanouriakis et al
Free

Antonis Fanouriakis, Nikolaos Tziolos, George Bertsias, Dimitrios T Boumpas

doi: 10.1136/annrheumdis-2021-221151
Correspondence
Correspondence on “Update on the diagnosis and management of systemic lupus erythematosus” by Fanouriakis et al
Free

Zhuochao Zhou, Yijun You, Fan Wang, Yue Sun, Jialin Teng, Honglei Liu, Xiaobing Cheng, Yutong Su, Hui Shi, Chengde Yang, Junna Ye

doi: 10.1136/annrheumdis-2021-220897

July 22, 2021

Correspondence response
Response to: ‘Correspondence on ‘Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial’’ by McGonagle et al
Free

Maja Skov Kragsnaes, Jens Kjeldsen, Hans Christian Horn, Heidi Lausten Munk, Jens Kristian Pedersen, Søren Andreas Just, Palle Ahlquist, Jesper Rømhild Davidsen, Anna Christine Nilsson, Richard Röttger, Mogens Kruhøffer, Julian R Marchesi, Karsten Kristiansen, Robin Christensen, Torkell Ellingsen

doi: 10.1136/annrheumdis-2021-220910

July 05, 2021

Correspondence
Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis’
Free

Quirine A Dumoulin, Xanthe M E Matthijssen, Fenne Wouters, Doortje I Krijbolder, Ellis Niemantsverdriet, Annette H M van der Helm-van Mil

doi: 10.1136/annrheumdis-2021-220511
Correspondence
Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’
Free

Weijie Wang, Yung-Heng Lee, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2021-220938
Correspondence response
Response to: ‘Correspondence on ‘Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis’’ by Dumoulin et al
Free

Irina Gessl, Daniel Aletaha, Peter Mandl

doi: 10.1136/annrheumdis-2021-220922

July 02, 2021

Correspondence
Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’
Free

Fernando Montero, Isabel Castrejón, Julia Martínez-Barrio, Juan Carlos Nieto-González, Javier Rivera, José María Álvaro-Gracia, Juan Molina Collada

doi: 10.1136/annrheumdis-2021-220941
Correspondence response
Response to ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’’ by Montero et al
Free

Alessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro

doi: 10.1136/annrheumdis-2021-220959

June 30, 2021

Correspondence
Correspondence on ‘Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial’
Free

Siddharth Jain, Varun Dhir

doi: 10.1136/annrheumdis-2021-220816
Correspondence response
Response to: ‘Correspondence on ‘Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial’’ by Jain and Dhir et al
Free

Veerle Stouten, René Westhovens, Sofia Pazmino, Diederik De Cock, Kristien Van der Elst, Johan Joly, Delphine Bertrand, Patrick Verschueren

doi: 10.1136/annrheumdis-2021-220857

June 29, 2021

Correspondence response
Response to: ‘Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’’ by Cai and Peng
Free

Anna Molto, Désirée van der Heijde, Filip E Van den Bosch, Maxime Dougados

doi: 10.1136/annrheumdis-2021-220913
Correspondence
Correspondence on ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’
Free

Guoqi Cai, Xiaoqing Peng

doi: 10.1136/annrheumdis-2021-220904

June 25, 2021

Correspondence response
Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
Free

James Cheng-Chung Wei, Tae-Hwan Kim, Mitsumasa Kishimoto, Naoki Ogusu, Haeyoun Jeong, Shigeto Kobayashi

doi: 10.1136/annrheumdis-2021-220788
Correspondence
Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomized, placebo-controlled, phase 3 trial’
Free

Yan Zhao, Jin-Xian Huang

doi: 10.1136/annrheumdis-2021-220759

June 23, 2021

Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Klopfenstein et al
Free

Robert BM Landewé, Sofia Ramiro, Rémy L M Mostard

doi: 10.1136/annrheumdis-2021-220787
Correspondence
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’

Timothée Klopfenstein, Vincent Gendrin, Thierry Conrozier, Aurélie Gerazime, Marc Puyraveau, Souheil Zayet

doi: 10.1136/annrheumdis-2021-220771

June 22, 2021

Correspondence
Correspondence on ‘Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial’
Free

Dennis G McGonagle, Charlie Bridgewood, Helena Marzo-Ortega

doi: 10.1136/annrheumdis-2021-220871

June 10, 2021

Correspondence response
Response to: ‘Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank’’ by Takei et al
Free

Gabriela Sandoval-Plata, Kevin Morgan, Abhishek Abhishek

doi: 10.1136/annrheumdis-2021-220785
Correspondence
Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank’
Free

Riku Takei, Nicholas A Sumpter, Amanda Phipps-Green, Murray Cadzow, Ruth K Topless, Richard J Reynolds, Tony R Merriman

doi: 10.1136/annrheumdis-2021-220769

June 07, 2021

Correspondence response
Response to: ‘Correspondence on: ‘Warfarin use and risk of knee and hip replacements’’ by He et al
Free

Priyanka Ballal, Christine Peloquin, Cindy Germaine Boer, Tuhina Neogi

doi: 10.1136/annrheumdis-2021-220855
Correspondence
Correspondence on ‘Warfarin use and risk of knee and hip replacements’
Free

Na He, Zhenwei Fang, Xiaotong Li, Suodi Zhai

doi: 10.1136/annrheumdis-2021-220819

May 26, 2021

Correspondence response
Response to: ‘Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’ by Gong and Zhang and Lin et al
Free

Shahab Abtahi, Johanna H M Driessen, Andrea M Burden, Patrick C Souverein, Joop P van den Bergh, Annelies Boonen

doi: 10.1136/annrheumdis-2021-220477
Correspondence
Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’
Free

Tsung-Kun Lin, Lung-Fa Pan, Gwo-Ping Jong

doi: 10.1136/annrheumdis-2021-220453
Correspondence
Correspondence on ‘Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study’
Free

Zhen Gong, Fangjie Zhang

doi: 10.1136/annrheumdis-2021-220494

May 17, 2021

Correspondence response
Response to: ‘Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?’ by Su et al
Free

Xenofon Baraliakos, Adrian Richter, Carsten O Schmidt, Juergen Braun

doi: 10.1136/annrheumdis-2021-220632
Correspondence
Correspondence on ‘Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?’
Free

Chun-Lin Su, Jhih-Wei Chen, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2021-220567

May 13, 2021

Correspondence response
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Rosenbaum et al
Free

Kimme L Hyrich, Martin Schäfer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C Robinson, Jinoos Yazdany, Pedro M Machado

doi: 10.1136/annrheumdis-2021-220613
Correspondence
Correspondence on ‘Warfarin use and risk of knee and hip replacements’
Free

Chao Cheng, Fangjie Zhang

doi: 10.1136/annrheumdis-2021-220580
Correspondence response
Response to: ‘Correspondence on ‘Warfarin use and risk of knee and hip replacements’’ by Cheng and Zhang
Free

Tuhina Neogi, Christine Peloquin, Priyanka Ballal, Cindy Germaine Boer

doi: 10.1136/annrheumdis-2021-220601
Correspondence
Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’
Free

James Todd Rosenbaum, Michael H Weisman, Cassie Shafer, Elin Aslanyan, Richard A Howard, Kimberly Ogle, Hedley Hamilton, John D Reveille, Kevin L Winthrop, Dongseok Choi

doi: 10.1136/annrheumdis-2021-220588

May 12, 2021

Correspondence response
Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al
Free

Marcia A Friedman, Kevin L Winthrop

doi: 10.1136/annrheumdis-2021-220398
Correspondence
Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’
Free

Desiree Tampe, Peter Korsten, Samy Hakroush, Martin Sebastian Winkler, Björn Tampe

doi: 10.1136/annrheumdis-2021-220382

April 27, 2021

Correspondence response
Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al
Free

Veerle F A M Derksen, Diane van der Woude

doi: 10.1136/annrheumdis-2021-220516
Correspondence
Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’
Free

Rashmi Roongta, Arghya Chattopadhyay, Alakendu Ghosh

doi: 10.1136/annrheumdis-2021-220479

April 26, 2021

Correspondence response
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al
Free

Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé

doi: 10.1136/annrheumdis-2021-220474
Correspondence
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
Free

Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas

doi: 10.1136/annrheumdis-2021-220411

April 21, 2021

Correspondence
Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’
Free

Hercílio Martelli Júnior, Nelson Pereira Marques, Nádia Carolina Teixeira Marques, Edson Gomes de Lucena, Daniella Reis B Martelli, Eduardo A Oliveira

doi: 10.1136/annrheumdis-2021-220410

April 09, 2021

Correspondence
Correspondence on ‘Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study’
Free

Liang En Wee, Edwin Philip Conceicao, Jing Yuan Tan, Julian Thumboo, Indumathi Venkatachalam

doi: 10.1136/annrheumdis-2021-220462

April 02, 2021

Correspondence
Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus’
Free

Ezgi Deniz Batu, Ummusen Kaya Akca, Ozge Basaran, Yelda Bilginer, Seza Ozen

doi: 10.1136/annrheumdis-2021-220246
Correspondence response
Response to: ‘Correspondence on ‘Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus’ by Batu et al
Free

Christina Adamichou, George Bertsias

doi: 10.1136/annrheumdis-2021-220262
Correspondence response
Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by de Wolff et al
Free

Renaud Felten, Jacques-Eric Gottenberg

doi: 10.1136/annrheumdis-2021-220220

March 31, 2021

Correspondence
Correspondence on: ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’
Free

Alojzija Hočevar, Aleš Ambrožič, Matija Tomšič

doi: 10.1136/annrheumdis-2021-220290
Correspondence response
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al
Free

Philipp Gauckler, Erica L Bettac, Andreas Kronbichler

doi: 10.1136/annrheumdis-2021-220324

Pages